Wednesday, February 8, 2012 Last update: 10:34 PM
The Best of U.S. Company Technology News
Now being accepted at FreshNews.com. See our complete guidelines.
Trade Events
Celldex Therapeutics, Inc.
News articles for Celldex Therapeutics, Inc.:
Wednesday, January 18, 2012
- Celldex Therapeutics to Host Research and Development Day Highlighting Oncology PipelineCelldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it will host a research and development day for the investment community on Monday, January 23, 2012 at 8:30 am ... read more
Tuesday, January 17, 2012
- Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that dosing has initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects. The study is ... read more
Wednesday, January 4, 2012
- Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory PopulationsCelldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that patient screening has initiated in a Phase 2 trial of rindopepimut in combination with Avastin® in patients with recurrent ... read more
Wednesday, December 21, 2011
- Celldex Completes Accrual of CDX-011 Phase 2b “EMERGE” Study in Advanced Breast CancerCelldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it has completed accrual of the EMERGE study, a randomized Phase 2b study evaluating CDX-011 (glembatumumab vedotin) in patients with ... read more
Monday, December 12, 2011
- Celldex Therapeutics Presents Novel Preclinical Data on CDX-1127 at the American Society of Hematology Meeting in San DiegoCelldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that new preclinical data on its therapeutic antibody program, CDX-1127, was presented in a poster presentation at the 2011 American Society ... read more
Wednesday, November 2, 2011
- Celldex Reports Third Quarter 2011 Financial ResultsCelldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the third quarter and nine months ended September 30, 2011. Celldex reported a net loss of $11.8 million, ... read more
Monday, October 31, 2011
- Celldex Therapeutics Announces Orphan Drug Designation in the European Union for Rindopepimut, a Novel EGFRvIII Vaccine for GlioblastomaCelldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the European Medicines Agency (EMA) has granted orphan drug designation for rindopepimut for the treatment of Glioblastoma (GB). GB is ... read more
Tuesday, October 25, 2011
- Celldex Therapeutics to Participate on Business Development Panel at BIO-Europe® 2011 in Duesseldorf, GermanyCelldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer of Celldex Therapeutics, Inc., will participate with other deal ... read more
Friday, October 14, 2011
- Celldex Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry ConferenceCelldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at the BioCentury NewsMakers in the ... read more
Monday, August 22, 2011
- Celldex Announces In Vivo Efficacy Data for CDX-1135 in Pediatric Kidney Disease Reported at International Complement MeetingCelldex Therapeutics, Inc. (Nasdaq: CLDX) today announced key in vivo efficacy data for its CDX-1135 program from a collaboration with Drs. Richard Smith and Carla Nester at the ... read more